- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02770313
Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction (WONDERFUL)
The goal of this study is to determine how effective repeated fasting over 26 weeks (6 months) is at improving risk parameters that are surrogate endpoints for cardiovascular diseases, metabolic dysregulation and cognitive impairments.
Subjects will be randomized 1:1 to water-only fasting or to their ad libitum usual diet, with randomization performed within strata based on fasting history (≤180 hours or 181-720 hours of total fasting for >12 consecutive hours per episode in the previous two years). Subjects will be assessed at 4, 13 and 26 weeks following randomization.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Utah
-
Murray, Utah, United States, 84157
- Intermountain Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male or non-pregnant female, 21-70 years of age,
- who are not currently taking a statin medication,
- who have either pre-diabetes (clinical diagnosis, hemoglobin A1c ≥5.6%, or untreated fasting glucose > 100 mg/dL within 6 months of screening) and are not taking medications to control diabetes OR diagnosed, diet-controlled type 2 diabetes but do not require medications to control diabetes OR one or more of the components of the metabolic syndrome measured within 6 months of screening (other than fasting glucose level >100 mg/dL, i.e.: 1. systolic blood pressure ≥130 mmHg, or diastolic ≥85 mmHg, or use of an antihypertensive medication, 2. high-density lipoprotein cholesterol <40 mg/dL for males or <50 mg/dL for females, 3. triglycerides ≥150 mg/dL or use of a non-statin triglyceride-lowering medication (e.g., fibrate, niacin), 4. waist circumference ≥40 inches (102 cm) for males or ≥35 inches (88 cm) for females, or body mass index >25 kg/m2),
- are 21-39 years of age with LDL-C (measured within six months of screening) of 90-189 mg/dL OR are 40-70 years of age with LDL-C of 90-159 mg/dL OR are 21-70 years of age with LDL-C of 90 mg/dL or greater who have tried statins and stopped due to intolerance to the medications or who have one or more contraindications to statins and thus cannot take them but meet other study inclusion and exclusion criteria.
- Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.
Exclusion Criteria:
- Pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception. Women who become pregnant after enrollment in the study will be withdrawn for the health of the mother and baby.
- Individuals who have fasted more than 15 hours per episode more than once per month during the past two years (i.e., >720 hours over two years), except for those who fast during multiple weeks once per year (e.g., Muslim, Baha'i) who will be allowed to begin participation starting at two weeks after their preferred annual period of fasting ends (e.g., Ramadan or the Baha'i fast) and ending at six months prior to the beginning of the next annual observance, as long as they do not fast routinely outside of the one annual period of fasting.
- Refusal to drink water while fasting.
- Prior diagnosis of a chronic disease (i.e., defined as symptomatic coronary artery disease, coronary revascularization, myocardial infarction, unstable angina, stroke, transient ischemic attack, pulmonary embolism, peripheral vascular thromboembolism, chronic kidney disease stage III or higher, chronic obstructive pulmonary disease, immunodeficiency, solid organ transplant, eating disorder, type I diabetes, dementia, traumatic brain injury including post-concussive syndrome, and cancer of any type within the last 5 years other than cancer of the skin excluding melanoma).
- Pre-diabetics or diabetics on diabetes medication.
- Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.
- Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intermittent Fasting
Water-only Intermittent Fasting
|
Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
|
No Intervention: Control
ad libitum Usual Diet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change score of low density lipoprotein cholesterol
Time Frame: 26 weeks
|
26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change score for Homeostatic Model Assessment - Insulin Resistance
Time Frame: 26 weeks
|
26 weeks
|
Change score for Metabolic Syndrome Score
Time Frame: 26 weeks
|
26 weeks
|
Change score for brain-derived neurotrophic factor (BDNF) level
Time Frame: 26 weeks
|
26 weeks
|
Change score for the MicroCog test's general cognitive proficiency index score
Time Frame: 26 weeks
|
26 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change score for gut microbiota composition based on 16S rDNA sequencing
Time Frame: 26 weeks
|
Change score for gut microbiota composition based on 16S rDNA sequencing among N=30 participants who opt in to this pre-specified substudy. Shannon's diversity index will be used because it measures the uncertainty in finding a specific type of microbe from one that is randomly selected from a stool sample. The index ranges from 0 to infinity. A higher value indicates that more diversity in species exists in the stool sample. It is calculated as negative one multiplied by the sum across each species of the proportion of the whole that the species constitutes in the stool multiplied by the natural log of that proportion. The change score will be the value at week 26 minus the value at baseline. |
26 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Benjamin D Horne, PhD, MPH, Intermountain Heart Institute
Publications and helpful links
General Publications
- Bartholomew CL, Muhlestein JB, May HT, Le VT, Galenko O, Garrett KD, Brunker C, Hopkins RO, Carlquist JF, Knowlton KU, Anderson JL, Bailey BW, Horne BD. Randomized controlled trial of once-per-week intermittent fasting for health improvement: the WONDERFUL trial. Eur Heart J Open. 2021 Sep 3;1(2):oeab026. doi: 10.1093/ehjopen/oeab026. eCollection 2021 Sep.
- Horne BD, Anderson JL, May HT, Le VT, Galenko O, Drakos SG, Bair TL, Knowlton KU, Muhlestein JB. Intermittent fasting and changes in Galectin-3: A secondary analysis of a randomized controlled trial of disease-free subjects. Nutr Metab Cardiovasc Dis. 2022 Jun;32(6):1538-1548. doi: 10.1016/j.numecd.2022.03.001. Epub 2022 Mar 7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 1050163
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intermittent Fasting
-
Istanbul Training and Research HospitalCompleted
-
Okan UniversityEnrolling by invitation
-
Josip Juraj Strossmayer University of OsijekCompleted
-
University of the PunjabCompleted
-
University of BariCompleted
-
USDA, Western Human Nutrition Research CenterUniversity of California, DavisCompletedCardiovascular Risk Factor | Athletic Performance | Fasting | Resting Energy Expenditure | Intermittent FastingUnited States
-
University of AlicanteUniversidad Católica San Antonio de MurciaCompletedBody Composition | Intermittent Fasting | Physical PerformanceSpain
-
Nottingham Trent UniversityActive, not recruitingTime Restricted Feeding | Intermittent FastingUnited Kingdom
-
Universitaet InnsbruckTirol Kiniken GmbHActive, not recruitingSmoking Cessation | Healthy | Healthy Lifestyle | Intermittent FastingAustria
Clinical Trials on Intermittent Fasting
-
H. Lee Moffitt Cancer Center and Research InstituteNot yet recruitingPancreatitis | Pancreatitis, Chronic | Pancreatitis, Acute | Pancreas Disease | Acute Recurrent PancreatitisUnited States
-
Mahidol UniversityHealth Systems Research InstituteEnrolling by invitationWeight Loss | Obese | Intermittent Fasting | Behavioral Economic | HOMA-IRThailand
-
Ohio State UniversityNational Psoriasis FoundationRecruitingPsoriasis | Psoriatic ArthritisUnited States
-
Menoufia UniversityRecruitingLocally Advanced Breast Cancer | Intermittent FastingEgypt
-
University of CalgaryCrohn's and Colitis FoundationNot yet recruiting
-
Washington University School of MedicineCompletedRelapsing Remitting Multiple SclerosisUnited States
-
Charite University, Berlin, GermanyWestfälische Wilhelms-Universität MünsterCompleted
-
Istanbul Training and Research HospitalCompleted
-
Ministry of Health, MalaysiaCompletedObesity | Intermittent FastingMalaysia
-
gino gaddiniTerminatedPre-diabetes | Diabetes Type 2United States